Details of Disease

General Information of Disease (ID: DISO70G5)

• Disease Name: Lyme disease
• Synonyms: Bannworth's syndrome; Lyme disease; Borreliella burgdorferi infectious disease; Borrelia burgdorferi infection; Borreliella burgdorferi caused disease or disorder; Lyme borreliosis; neurological Lyme disease; neuroborreliosis; Bannwarth syndrome; Borreliella burgdorferi disease or disorder; Borrelia; Lyme neuroborreliosis
• Disease Class: 1C1G: Lyme borreliosis
• Definition: Lyme disease (named after the towns in the USA where the disease was first identified) is a bacterial infection caused by Borrelia burgdorferi.
• Disease Hierarchy:
  DIS8ZVFW: Primary bacterial infectious disease
  DISFY0K2: Tick-borne infectious disease
  DIS76DJE: Leptospira infection
  DISEM33Q: Infectious disease
  DISO70G5: Lyme disease
• ICD Code:
  ICD-11: ICD-11: 1C1G
  ICD-10: ICD-10: A69.2
  ICD-9: ICD-9: 88.81
  Expand ICD-11: '1C1G
  Expand ICD-10: 'A69.2
  Expand ICD-9: 88.81
• Disease Identifiers:
  MONDO ID: MONDO_0019632
  MESH ID: D008193
  UMLS CUI: C0024198
  MedGen ID: 44213
  Orphanet ID: 91546
  SNOMED CT ID: 23502006

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 4 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Demeclocycline	DMZEPFJ	Approved	Small molecular drug	[1]
Lyme disease vaccine	DMCHW8R	Approved	NA	[1]
LYMErix	DMJXWOY	Approved	NA	[2]
OspA lipoprotein	DMF5ZB3	Approved	Vaccine	[3]

This Disease is Treated as An Indication in 3 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PF-07307405	DMOCO1F	Phase 3	Vaccine	[4]
VLA15	DMMACXS	Phase 2	Vaccine	[5]
VLA15-101	DMDNVJY	Phase 1	NA	[6]

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
VGV-L	DMP8QJL	Investigative	NA	[7]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 13 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CDK5R1	TTBYM6V	moderate	Altered Expression	[8]
DCN	TTB3XAN	moderate	Altered Expression	[9]
ELK3	TT5OJMV	moderate	Biomarker	[10]
CD300A	TTI2YFK	Strong	Biomarker	[11]
EPHA5	TTV9KOD	Strong	Biomarker	[12]
FHL1	TTI7ENL	Strong	Biomarker	[13]
IFNL1	TTM624L	Strong	Altered Expression	[14]
IL12A	TTRTK6Y	Strong	Altered Expression	[8]
MAZ	TT059DA	Strong	Biomarker	[15]
RAB22A	TTAJ746	Strong	Biomarker	[16]
RNMT	TTG45HY	Strong	Biomarker	[17]
TLR1	TTW14D0	Strong	Genetic Variation	[18]
TLR2	TTY7ZHS	Strong	Biomarker	[19]

This Disease Is Related to 1 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
NT5C2	DE1DOKJ	moderate	Genetic Variation	[20]

This Disease Is Related to 44 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CCNH	OTKDU3SR	moderate	Biomarker	[21]
CD8B	OTMZ1T7J	moderate	Biomarker	[21]
EBPL	OT59J1GY	moderate	Biomarker	[10]
HNRNPD	OT5UO1FA	moderate	Biomarker	[21]
NUP37	OTPZH72U	moderate	Biomarker	[21]
AK6	OT84OHHP	Strong	Biomarker	[22]
ATP6V0D1	OT9GU2NW	Strong	Biomarker	[23]
BLZF1	OT5QD8FG	Strong	Biomarker	[24]
CANX	OTYP1F6J	Strong	Biomarker	[25]
CD180	OTITK5E6	Strong	Biomarker	[26]
CD1B	OT4D5EG7	Strong	Biomarker	[27]
CD48	OT83ZNPP	Strong	Biomarker	[28]
CDCA5	OTZLCQ5U	Strong	Altered Expression	[8]
CDK5R2	OTNUTLPU	Strong	Biomarker	[23]
CPVL	OTOJL31C	Strong	Biomarker	[29]
DCTN3	OTQOSUES	Strong	Biomarker	[30]
DYNC1H1	OTD1KRKO	Strong	Biomarker	[30]
EEF1A1	OT00THXS	Strong	Biomarker	[31]
ENO2	OTRODL0T	Strong	Biomarker	[32]
EXOSC1	OTB1QQJJ	Strong	Biomarker	[33]
FAM20C	OTW5YZ7X	Strong	Biomarker	[34]
FCN2	OTTHJBKZ	Strong	Altered Expression	[8]
GCHFR	OTEOT8GI	Strong	Altered Expression	[8]
HACD1	OTEC7EP7	Strong	Biomarker	[35]
IFIT3	OTPGHZB9	Strong	Genetic Variation	[36]
KARS1	OT0EU4SV	Strong	Biomarker	[37]
KRT10	OTSVRD3Q	Strong	Biomarker	[38]
MLIP	OTMT7AII	Strong	Biomarker	[22]
MNAT1	OTXLOYCB	Strong	Altered Expression	[8]
NELFCD	OTOLTZPU	Strong	Biomarker	[39]
NOP53	OTA2YKO6	Strong	Genetic Variation	[36]
NRSN1	OT1KKXC8	Strong	Altered Expression	[40]
POLD3	OTEQEFQ2	Strong	Biomarker	[41]
PPP1R14A	OTQODWZB	Strong	Altered Expression	[42]
PTGES3	OTPPQWI0	Strong	Biomarker	[43]
R3HCC1L	OT776PX2	Strong	Biomarker	[28]
RAB5A	OTFR2KM4	Strong	Biomarker	[16]
RHBDL2	OTJPJ8N6	Strong	Biomarker	[44]
RHOBTB2	OT2DATFX	Strong	Biomarker	[45]
RRP1	OT4A8HR3	Strong	Biomarker	[46]
SELENOK	OTKM7N7P	Strong	Biomarker	[47]
SENP6	OT05LLF4	Strong	Biomarker	[48]
SRI	OT4R3EAC	Strong	Genetic Variation	[49]
TMED10	OTUXSHH7	Strong	Biomarker	[43]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010423)
• [3] Infection of mice with lyme disease spirochetes constitutively producing outer surface proteins a and B. Infect Immun. 2007 Jun;75(6):2786-94.
• [4] ClinicalTrials.gov (NCT05634811) A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY OF A 6-VALENT OspA-BASED LYME DISEASE VACCINE (VLA15) IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE. U.S.National Institutes of Health.
• [5] ClinicalTrials.gov (NCT03970733) Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis. U.S. National Institutes of Health.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [8] Differential expression of Borrelia burgdorferi genes during erythema migrans and Lyme arthritis.J Infect Dis. 1998 Oct;178(4):1198-201. doi: 10.1086/515684.
• [9] Co-culture of human fibroblasts and Borrelia burgdorferi enhances collagen and growth factor mRNA.Arch Dermatol Res. 2018 Mar;310(2):117-126. doi: 10.1007/s00403-017-1797-1. Epub 2017 Dec 6.
• [10] Expression of Borrelia burgdorferi erp genes during infection of non-human primates.Microb Pathog. 2005 Jul-Aug;39(1-2):27-33. doi: 10.1016/j.micpath.2005.04.001.
• [11] IrC2/Bf - A yeast and Borrelia responsive component of the complement system from the hard tick Ixodes ricinus.Dev Comp Immunol. 2018 Feb;79:86-94. doi: 10.1016/j.dci.2017.10.012. Epub 2017 Oct 20.
• [12] Comparison of MKP and BSK-H media for the cultivation and isolation of Borrelia burgdorferi sensu lato.PLoS One. 2017 Feb 7;12(2):e0171622. doi: 10.1371/journal.pone.0171622. eCollection 2017.
• [13] Crystal structure of Borrelia burgdorferi outer surface protein BBA69 in comparison to the paralogous protein CspA.Ticks Tick Borne Dis. 2019 Aug;10(5):1135-1141. doi: 10.1016/j.ttbdis.2019.06.009. Epub 2019 Jun 11.
• [14] Induction of type I and type III interferons by Borrelia burgdorferi correlates with pathogenesis and requires linear plasmid 36.PLoS One. 2014 Jun 19;9(6):e100174. doi: 10.1371/journal.pone.0100174. eCollection 2014.
• [15] Serum amyloid A-activating factor-1 (SAF-1) transgenic mice are prone to develop a severe form of inflammation-induced arthritis.J Immunol. 2004 Oct 1;173(7):4684-91. doi: 10.4049/jimmunol.173.7.4684.
• [16] ER-Coordinated Activities of Rab22a and Rab5a Drive Phagosomal Compaction and Intracellular Processing of Borrelia burgdorferi by Macrophages.Cell Rep. 2015 Sep 22;12(11):1816-30. doi: 10.1016/j.celrep.2015.08.027. Epub 2015 Sep 3.
• [17] Differential gene expression in chronic inflammatory demyelinating polyneuropathy (CIDP) skin biopsies.J Neurol Sci. 2010 Mar 15;290(1-2):115-22. doi: 10.1016/j.jns.2009.10.006. Epub 2009 Nov 17.
• [18] Association of Toll-like receptor 2 Arg753Gln and Toll-like receptor 1 Ile602Ser single-nucleotide polymorphisms with leptospirosis in an Argentine population.Acta Trop. 2015 Jun;146:73-80. doi: 10.1016/j.actatropica.2015.03.007. Epub 2015 Mar 14.
• [19] Small-scale spatial variation in infection risk shapes the evolution of a Borrelia resistance gene in wild rodents.Mol Ecol. 2018 Sep;27(17):3515-3524. doi: 10.1111/mec.14812. Epub 2018 Aug 6.
• [20] The Borrelia burgdorferi c-di-GMP Binding Receptors, PlzA and PlzB, Are Functionally Distinct.Front Cell Infect Microbiol. 2018 Jul 11;8:213. doi: 10.3389/fcimb.2018.00213. eCollection 2018.
• [21] The Borrelia burgdorferi 37-kilodalton immunoblot band (P37) used in serodiagnosis of early lyme disease is the flaA gene product.J Clin Microbiol. 1999 Mar;37(3):548-52. doi: 10.1128/JCM.37.3.548-552.1999.
• [22] Genomic and phenotypic characterization of Borrelia afzelii BO23 and Borrelia garinii CIP 103362.PLoS One. 2018 Jun 26;13(6):e0199641. doi: 10.1371/journal.pone.0199641. eCollection 2018.
• [23] Proteomics in human disease: cancer, heart and infectious diseases.Electrophoresis. 1999 Jul;20(10):2100-10. doi: 10.1002/(SICI)1522-2683(19990701)20:10<2100::AID-ELPS2100>3.0.CO;2-D.
• [24] Evaluation of genetic divergence of borrelial isolates from Lyme disease patients in Hokkaido, Japan, by rRNA gene probes.J Clin Microbiol. 1993 Aug;31(8):2044-8. doi: 10.1128/jcm.31.8.2044-2048.1993.
• [25] Characterization of the vls antigenic variation loci of the Lyme disease spirochaetes Borrelia garinii Ip90 and Borrelia afzelii ACAI.Mol Microbiol. 2003 Mar;47(5):1407-17. doi: 10.1046/j.1365-2958.2003.03386.x.
• [26] A multi-omic analysis reveals the regulatory role of CD180 during the response of macrophages to Borrelia burgdorferi.Emerg Microbes Infect. 2018 Mar 7;7(1):19. doi: 10.1038/s41426-017-0018-5.
• [27] CD1b presents self and Borrelia burgdorferi diacylglycerols to human T cells.Eur J Immunol. 2019 May;49(5):737-746. doi: 10.1002/eji.201847949. Epub 2019 Mar 20.
• [28] Lsa63, a newly identified surface protein of Leptospira interrogans binds laminin and collagen IV.J Infect. 2010 Jan;60(1):52-64. doi: 10.1016/j.jinf.2009.10.047. Epub 2009 Oct 30.
• [29] Eliminating Factor H-Binding Activity of Borrelia burgdorferi CspZ Combined with Virus-Like Particle Conjugation Enhances Its Efficacy as a Lyme Disease Vaccine.Front Immunol. 2018 Feb 8;9:181. doi: 10.3389/fimmu.2018.00181. eCollection 2018.
• [30] A chromosomal Borrelia burgdorferi gene encodes a 22-kilodalton lipoprotein, P22, that is serologically recognized in Lyme disease.J Clin Microbiol. 1994 Apr;32(4):876-83. doi: 10.1128/jcm.32.4.876-883.1994.
• [31] Borrelia burgdorferi elongation factor EF-Tu is an immunogenic protein during Lyme borreliosis.Emerg Microbes Infect. 2015 Sep 2;4(9):e54. doi: 10.1038/emi.2015.54.
• [32] Autoimmunity against a glycolytic enzyme as a possible cause for persistent symptoms in Lyme disease.Med Hypotheses. 2018 Jan;110:1-8. doi: 10.1016/j.mehy.2017.10.024. Epub 2017 Oct 26.
• [33] Molecular analysis of the channel-forming protein P13 and its paralogue family 48 from different Lyme disease Borrelia species.Microbiology (Reading). 2004 Mar;150(Pt 3):549-559. doi: 10.1099/mic.0.26728-0.
• [34] A high-throughput genetic screen identifies previously uncharacterized Borrelia burgdorferi genes important for resistance against reactive oxygen and nitrogen species.PLoS Pathog. 2017 Feb 17;13(2):e1006225. doi: 10.1371/journal.ppat.1006225. eCollection 2017 Feb.
• [35] Analysis of a flagellar filament cap mutant reveals that HtrA serine protease degrades unfolded flagellin protein in the periplasm of Borrelia burgdorferi.Mol Microbiol. 2019 Jun;111(6):1652-1670. doi: 10.1111/mmi.14243. Epub 2019 Apr 26.
• [36] Taxonomic classification of 29 Borrelia burgdorferi strains isolated from patients with Lyme borreliosis: a comparison of five different phenotypic and genotypic typing schemes.Med Microbiol Immunol. 1994 Dec;183(6):325-41. doi: 10.1007/BF00196683.
• [37] Differentiation of Borrelia burgdorferi sensu lato strains using class I lysyl-tRNA synthetase-encoding genes.Med Microbiol Immunol. 2003 May;192(2):79-83. doi: 10.1007/s00430-002-0149-7. Epub 2002 Sep 25.
• [38] Autoantibodies from synovial lesions in chronic, antibiotic treatment-resistant Lyme arthritis bind cytokeratin-10.J Immunol. 2006 Aug 15;177(4):2486-94. doi: 10.4049/jimmunol.177.4.2486.
• [39] Decreased up-regulation of the interleukin-12Rbeta2-chain and interferon-gamma secretion and increased number of forkhead box P3-expressing cells in patients with a history of chronic Lyme borreliosis compared with asymptomatic Borrelia-exposed individuals.Clin Exp Immunol. 2007 Jan;147(1):18-27. doi: 10.1111/j.1365-2249.2006.03245.x.
• [40] Analysis of a VMP-like sequence (vls) locus in Borrelia garinii and Vls homologues among four Borrelia burgdorferi sensu lato species.FEMS Microbiol Lett. 2001 May 15;199(1):39-45. doi: 10.1111/j.1574-6968.2001.tb10648.x.
• [41] Sequence typing reveals extensive strain diversity of the Lyme borreliosis agents Borrelia burgdorferi in North America and Borrelia afzelii in Europe.Microbiology (Reading). 2004 Jun;150(Pt 6):1741-1755. doi: 10.1099/mic.0.26944-0.
• [42] Osp17, a novel immunodominant outer surface protein of Borrelia afzelii: recombinant expression in Escherichia coli and its use as a diagnostic antigen for serodiagnosis of Lyme borreliosis.Med Microbiol Immunol. 1999 May;187(4):213-9. doi: 10.1007/s004300050095.
• [43] Molecular characterization and expression of p23 (OspC) from a North American strain of Borrelia burgdorferi.Infect Immun. 1993 Dec;61(12):5097-105. doi: 10.1128/iai.61.12.5097-5105.1993.
• [44] The RpoS Gatekeeper in Borrelia burgdorferi: An Invariant Regulatory Scheme That Promotes Spirochete Persistence in Reservoir Hosts and Niche Diversity.Front Microbiol. 2019 Aug 21;10:1923. doi: 10.3389/fmicb.2019.01923. eCollection 2019.
• [45] Establishment of enzyme-linked immunosorbent assay using purified recombinant 83-kilodalton antigen of Borrelia burgdorferi sensu stricto and Borrelia afzelii for serodiagnosis of Lyme disease.J Clin Microbiol. 1995 Oct;33(10):2596-600. doi: 10.1128/jcm.33.10.2596-2600.1995.
• [46] Positive and Negative Regulation of Glycerol Utilization by the c-di-GMP Binding Protein PlzA in Borrelia burgdorferi.J Bacteriol. 2018 Oct 23;200(22):e00243-18. doi: 10.1128/JB.00243-18. Print 2018 Nov 15.
• [47] Is selenoprotein K required for Borrelia burgdorferi infection within the tick vector Ixodes scapularis?.Parasit Vectors. 2019 Jun 7;12(1):289. doi: 10.1186/s13071-019-3548-y.
• [48] Lyme Disease Risks in Europe under Multiple Uncertain Drivers of Change.Environ Health Perspect. 2019 Jun;127(6):67010. doi: 10.1289/EHP4615. Epub 2019 Jun 24.
• [49] Immunolocalization of a 22 kDa protein (IPLA7, P22) of Borrelia burgdorferi.FEMS Microbiol Lett. 1996 May 1;138(2-3):215-9. doi: 10.1111/j.1574-6968.1996.tb08160.x.